RELiZORB
Fat malabsorption in enterally fed patients (e.g., cystic fibrosis, short bowel syndrome)
Phase 3Active
Key Facts
Indication
Fat malabsorption in enterally fed patients (e.g., cystic fibrosis, short bowel syndrome)
Phase
Phase 3
Status
Active
Company
About Alcresta Therapeutics
Alcresta Therapeutics is a commercial-stage biotech company addressing a critical unmet need in enteral nutrition for patients with rare diseases. Its core technology is the RELiZORB cartridge, which contains immobilized lipase (iLipase) to break down fats in tube feeding formulas, mimicking pancreatic function. The company has achieved FDA clearance for expanded use in neonates and infants and is generating real-world evidence to support its product. Led by an experienced management team, Alcresta is positioned in the niche but essential markets of metabolic and rare diseases with a specialized drug delivery platform.
View full company profile